Jane Bradbury, The Lancet Infectious Diseases, Volume 11, Issue 2, Page 89, February 2011:
The current treatment for chronic hepatitis C virus (HCV) infection—pegylated interferon and ribavirin—is effective in less than half of patients infected with HCV genotypes 1 or 4.
Paradoxically, high plasma concentrations of the proinflammatory chemokine CXCL10 predict poor treatment responses.
A new study provides an explanation for this paradox by showing that CXCL10 in the plasma of non-responding patients exists as an amino-terminal truncated antagonist form that is ge ... The Lancet: To read this article in full you will need to login or make a payment